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Robotic Partial Nephrectomy for Posterior Tumors
Through a Retroperitoneal Approach Offers Decreased
Length of Stay Compared with the Transperitoneal Approach:
A Propensity-Matched Analysis
Matthew J. Maurice, MD,1 Jihad H. Kaouk, MD,1 Daniel Ramirez, MD,1 Sam B. Bhayani, MD,2
Mohamad E. Allaf, MD,3 Craig G. Rogers, MD,4 and Michael D. Stifelman, MD5
Abstract
Introduction: We sought to compare surgical outcomes between transperitoneal and retroperitoneal robotic
partial nephrectomy (RPN) for posterior tumors.
Patients and Methods: Using our multi-institutional RPN database, we reviewed 610 consecutive cases for
posterior renal masses treated between 2007 and 2015. Primary outcomes were complications, operative time,
length of stay (LOS), surgical margin status, and estimated glomerular filtration rate (eGFR) preservation.
Secondary outcomes were estimated blood loss, warm ischemia time (WIT), disease recurrence, and disease-
specific mortality. Due to significant differences in treatment year and tumor size between approaches, retro-
peritoneal cases were matched 1:4 to transperitoneal cases based on propensity scores using the greedy algorithm.
Outcomes were compared between approaches using the chi-square and Mann–Whitney U tests.
Results: After matching, 296 transperitoneal and 74 retroperitoneal cases were available for analysis, and
matched groups were well balanced in terms of treatment year, age, gender, race, American Society of An-
esthesiologists physical status classification (ASA) score, body mass index, tumor laterality, tumor size,
R.E.N.A.L. (radius, exophytic/endophytic properties, nearness of tumor to the collecting system or sinus,
anterior/posterior, location relative to polar lines) score, and hilar location. Compared with transperitoneal, the
retroperitoneal approach was associated with significantly shorter mean LOS (2.2 vs 2.6 days, p = 0.01), but
longer mean WIT (21 vs 19 minutes, p = 0.01). Intraoperative ( p= 0.35) and postoperative complications
( p = 0.65), operative time ( p= 0.93), positive margins ( p = 1.0), and latest eGFR preservation ( p = 0.25) were
not significantly different between approaches. No differences were detected in the other outcomes.
Conclusions: Among high-volume surgeons, transperitoneal and retroperitoneal RPN achieved similar out-
comes for posterior renal masses, although with slight differences in LOS and WIT. Retroperitoneal RPN may
be an effective option for the treatment of certain small posterior renal masses.
Keywords: robotics, renal cancer, laparoscopic approach
Introduction
In robotic partial nephrectomy (RPN), the optimal ap-proach for treating posterior renal masses is often debated.
There are several potential advantages of the retroperitoneal
approach over the transperitoneal approach.1,2 Namely, the
retroperitoneal approach avoids bowel manipulation, does not
require full kidney mobilization, allows direct access to the
renal hilum, and contains bleeding and urine leakage to the
retroperitoneal space, which altogether may save time, reduce
the risk of bowel injury (especially in the setting of prior ab-
dominal surgery), andminimize the risk of postoperative ileus.
However, the retroperitoneal approach may be more techni-
cally challenging than the transperitoneal approach due to the
limited working space of the retroperitoneum and less familiar
anatomic landmarks, which may lead to disorientation and
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inadvertent vascular injury.3 Prior studies comparing these
approaches have been limited by small single-institution
experiences.4–7 In fact, the need for a robust high-quality
observational study has been advocated.8 Our objective was to
compare surgical outcomes between the transperitoneal and
retroperitoneal approaches, specifically for posterior tumors,
in our large multi-institutional RPN database.
Patients and Methods
Study population
After obtaining institutional review board approval, we
queried our multi-institutional RPN database, which contains
comprehensive data on*2000 consecutive RPNs performed
by five high-volume robotic surgeons between 2007 and 2015.
The database includes each surgeon’s cumulative RPN expe-
rience for both transperitoneal and retroperitoneal cases. Three
surgeons contributed transperitoneal and retroperitoneal cases
to the cohort, while two surgeons contributed only transper-
itoneal cases. Anterior tumors were treated primarily using the
transperitoneal approach, while posterior tumors were treated
using either the transperitoneal approach or retroperitoneal
approach, with the decision based on patient history of prior
abdominal surgery and/or surgeon preference. Only RPN cases
for posterior tumors were included in the study. We utilized
radiology reports and nephrometry score when available to
identify patients with posterior tumors. The transperitoneal
and retroperitoneal approaches were performed using stan-
dardized techniques, as previously described.1,2,9
Study variables
Aside from approach, other variables studied included
treatment year, patient age, gender, race, American Society of
Anesthesiologists physical status classification (ASA), body
mass index (BMI), chronic kidney disease (stage 3 or greater),
tumor laterality, clinical tumor size, pathological T stage,
R.E.N.A.L. (radius, exophytic/endophytic properties, nearness
of tumor to the collecting system or sinus, anterior/posterior,
location relative to polar lines) nephrometry score,10 and hilar
tumor location.
Study outcomes
Outcome measures were selected a priori. To assess the
suggested benefits (i.e., decreased morbidity, expedited
recovery, shorter procedure time), oncological efficacy, and
functional efficacy of the retroperitoneal approach, we chose
intraoperative and 30-day postoperative complications,
length of stay (LOS), operative time, surgical margin status,
and estimated glomerular filtration rate (eGFR) preservation
for our primary outcomes. Secondary outcomes included
estimated blood loss, warm ischemia time (WIT), disease
recurrence, all-cause death, and disease-specific death.
Complications were graded using the Clavien–Dindo clas-
sification system. Overall (Clavien 1–5) and major (Clavien
3–5) postoperative complication rates were assigned based
on the most severe complication recorded per case. eGFR
was calculated using the MDRD equation. eGFR preserva-
tion was determined by dividing the latest eGFR by the
preoperative eGFR, expressed as a percentage.
Propensity matching
Differences between the retroperitoneal (n= 87) and trans-
peritoneal (n= 523) groups were evaluated using the Pearson
chi-square test for categorical variables and the Mann–
Whitney U test for ordinal and continuous variables. In the
unmatched cohort, treatment year and tumor size differed
significantly between the retroperitoneal and transperitoneal
groups (Table 1A). A 1:4 (retroperitoneal:transperitoneal)
propensity score-based match was performed using the greedy
nearest-neighbor algorithm. The completeness of the match
was assured by the fact that 85% (n= 74) of retroperitoneal
cases werematched, and no additionalmatches could bemade.
The goodness of thematch was evidenced in that no significant
differences remained between the groups after matching, and
matching was not improved by a 1:5 match.
Statistical analysis
Normally distributed variables are expressed as mean–
standard deviation. Non-normally distributed variables are
expressed as median (interquartile range [IQR]). Outcomes
were compared between the retroperitoneal and transperitoneal
approaches using the Pearson chi-square, Fisher exact, and
Mann–Whitney U tests. Statistical tests were performed using
SAS University Edition (SAS Institute, Inc., Cary, NC). All
tests were two-sided, and statistical significance was consid-
ered at p< 0.05.
Results
In the final matched cohort, 370 RPN cases for posterior
renal masses were available for analysis. The 4:1 match
yielded 74 retroperitoneal and 296 transperitoneal cases. The
matched groups were well balanced in terms of treatment
year, age, gender, race, ASA, BMI, chronic kidney disease,
tumor laterality, tumor size, T stage, R.E.N.A.L. score, and
hilar location (Table 1B). For the matched cohort, the median
tumor size was 2.5 cm (IQR 1.9–3.6 cm), and the median
R.E.N.A.L. score was 7 (IQR 6–9).
Mean LOS was significantly shorter for the retroperitoneal
approach compared with the transperitoneal approach (2.2 vs
2.6 days, p = 0.01). Intraoperative complications ( p= 0.35),
overall ( p = 0.65) and major ( p = 0.30) postoperative com-
plications, operative time ( p = 0.93), positive surgical mar-
gins ( p = 1.0), and eGFR preservation with 7 months of
median follow-up ( p = 0.25) were not significantly different
between approaches (Table 2).
Complications for the retroperitoneal and transperitoneal
approaches, respectively, included (in order of most to least
common) blood transfusion (2.7% vs 3.7%, p = 1.0), respi-
ratory problem (4.1% vs 2.7%, p = 0.47), infection (2.7% vs
1.7%, p= 0.63), angioembolization (1.4% vs 1.4%, p = 1.0),
nonischemic cardiovascular problem (0% vs 2.7%, p= 0.37),
ileus (0% vs 1.0%, p = 1.0), venous thromboembolism (0% vs
0.7%, p = 1.0), urine leak (0% vs 0.7%, p = 1.0), acute kidney
injury with oliguria or requiring hemodialysis (0% vs 0.3%,
p = 1.0), myocardial infarction (0% vs 0.3%, p = 1.0), wound
(0% vs 0.3%, p = 1.0), and kidney loss (0% vs 0.2%, p = 1.0).
Intraoperative complications in the transperitoneal group
included 1 adjacent organ injury, 1 open conversion, 0 hollow
viscus injuries, 0 vascular injuries, and 5 other intraoperative














































Table 1. Case Characteristics by Approach, Before and After Matching
(A) Before matching
Variables Total (N = 610) TA (n= 523) RA (n= 87) p
Median treatment year (IQR) 2012 (2010–2013) 2012 (2010–2013) 2013 (2011–2014) <0.01
Median age (IQR) 60 (52–66) 60 (52–66) 60 (50–66) 0.60
Male, n (%) 363 (59.5) 305 (58.3) 58 (66.7) 0.14
White, n (%) 488 (81.2) 416 (80.6) 72 (84.7) 0.37
Median ASA score (IQR) 3 (2–3) 3 (2–3) 2 (2–3) 0.27
Median BMI (IQR), kg/m2 29.4 (25.2–33.0) 29.3 (25.4–32.9) 29.7 (25.0–33.5) 0.99
Chronic kidney disease, n (%) 178 (29.2) 145 (27.7) 33 (37.9) 0.05
Median preoperative
eGFR (IQR), mL/min/1.73m2
77.1 (63.7–91.6) 77.6 (64.4–92.5) 81.6 (65.8–98.9) 0.14
Left side, n (%) 304 (50.1) 264 (50.6) 40 (47.1) 0.55
Median tumor size (IQR), cm 2.7 (1.9–3.7) 2.7 (2.0–3.8) 2.3 (1.8–3.2) 0.01
Pathological T stage, n (%)a 0.75
1 448 (92.8) 382 (92.5) 66 (94.3)
2 6 (1.2) 6 (1.5) 0
3 28 (5.8) 24 (5.8) 4 (5.7)
4 1 (0.21) 1 (0.24) 0
Median R.E.N.A.L. score (IQR) 7 (6–9) 7 (6–9) 7 (6–9) 0.60
Hilar location, n (%) 67 (14.1) 55 (13.2) 12 (21.1) 0.11
(B) After matching
Variables Total (N= 370) TA (n = 296) RA (n = 74) p
Median treatment year (IQR) 2012 (2011–2014) 2012 (2011–2014) 2013 (2011–2014) 0.89
Median age (IQR) 59 (52–66) 59 (52–66) 60 (50–65) 0.92
Male, n (%) 219 (59.2) 168 (56.8) 51 (68.9) 0.06
White, n (%) 296 (80.9) 235 (80.2) 61 (83.6) 0.51
Median ASA score (IQR) 3 (2–3) 3 (2–3) 2 (2–3) 0.56
Median BMI (IQR), kg/m2 29.1 (25.1–32.9) 29.4 (25.1–33.0) 30.0 (25.1–33.9) 0.42
Chronic kidney disease, n (%) 111 (30.0) 84 (28.4) 27 (36.5) 0.17
Median preoperative
eGFR (IQR), mL/min/1.73m2
77.6 (62.5–96.3) 77.0 (62.1–94.7) 83.6 (65.8–100.4) 0.89
Left side, n (%) 181 (49.2) 148 (50.0) 33 (45.8) 0.53
Median tumor size, cm (IQR) 2.5 (1.9–3.6) 2.5 (1.9–3.5) 2.4 (1.9–3.3) 0.59
Pathological T stage, n (%)a 0.87
1 276 (93.6) 218 (93.6) 58 (93.6)
2 0 0 0
3 18 (6.1) 14 (6.0) 4 (6.5)
4 1 (0.34) 1 (0.43) 0
Median R.E.N.A.L. score (IQR) 7 (6–9) 7 (6–9) 8 (6–9) 0.32
Hilar location, n (%) 43 (14.8) 33 (13.6) 10 (20.4) 0.22
aPathological T stage only applies to malignant tumors. There were 483 and 295 malignant tumors in the dataset before and after
matching, respectively. Bold type indicates statistical significance.
ASA=American Society of Anesthesiologists physical status classification; BMI = body mass index; eGFR = estimated glomerular
filtration rate; IQR = interquartile range; RA= retroperitoneal approach; R.E.N.A.L.= radius, exophytic/endophytic properties, nearness of
tumor to the collecting system or sinus, anterior/posterior, location relative to polar lines; TA= transperitoneal approach.
Table 2. Primary Outcomes by Approach
Outcomes Total TA RA p
Overall complications, n (%) 51 (13.8) 42 (14.2) 9 (12.2) 0.65
Major complications, n (%) 13 (3.5) 9 (3.0) 4 (5.4) 0.30
Intraoperative complications, n (%) 7 (1.9) 7 (2.4) 0 0.35
Mean operative time – SD, minutes 176– 58 176 – 58 176– 59 0.93
Mean LOS – SD, days 2.5 – 1.1 2.6 – 1.2 2.2 – 0.9 0.01
PSM, n (%) 6 (1.7) 5 (1.7) 1 (1.4) 1.00
GFR preservation at latest follow-up (%) 85.1 (74.4–99.8) 84.9 (73.6–99.7) 90.4 (76.7–106) 0.25
Median GFR follow-up (IQR), months 7.3 (0.6–24.2) 7.1 (0.5–24.0) 10.5 (2.6–24.9) 0.69
Bold type indicates statistical significance.
LOS= length of stay; PSM= positive surgical margins; SD = standard deviation.














































complications. There were no intraoperative complications in
the retroperitoneal group.
In regard to secondary outcomes, WIT was the only out-
come found to differ between approaches (Table 3). Com-
pared with the retroperitoneal approach, the transperitoneal
approach was associated with a significantly shorter WIT (19
vs 21 minutes, p= 0.01). Estimated blood loss was not signif-
icantly different between the retroperitoneal and transper-
itoneal approaches, respectively (150 vs 190mL, p= 0.18).
With a median overall follow-up of 15 months, the rates of
disease recurrence, all-cause death, and disease-specific death
did not differ significantly between approaches.
Discussion
Retroperitoneal and transperitoneal RPN are both surgical
options for the treatment of posterior renal masses.11 While
retroperitoneal RPN is technically feasible for the treatment
of anterior or lateral renal masses, it is a more challenging
operation due to increased external instrument clashing when
approaching the anterior renal surface through the retroper-
itoneal approach. However, it has been suggested that the
retroperitoneal approach is ideally suited for treatment of
posterior renal masses because it provides direct access to the
posterior surface of the kidney and renal hilum while avoiding
bowel manipulation and peritoneal violation.12,13 These un-
ique features of the retroperitoneal approach have theoretical
advantages, namely decreased operative time, decreased mor-
bidity, and expedited recovery due to less risk of ileus.
In clinical practice, there is inherent bias in selecting the
RPN approach based on tumor location and surgical history,
which has made direct comparisons between the two ap-
proaches difficult. Specifically, the transperitoneal approach
is used more for anterior tumors, and the retroperitoneal ap-
proach is used more for posterior tumors or for anterior tu-
mors in patients with prior abdominal surgery who may not
be candidates for transperitoneal surgery.14 Prior observa-
tional studies did not detect a difference in surgical outcomes
between approaches, except for potentially shorter operative
times with the retroperitoneal approach.4–6 However, these
studies were limited by small samples sizes and did not ac-
count for treatment selection bias, threatening the validity of
their results. In these single-center studies, sample size con-
straints prevented a specific analysis of outcomes for posterior
renal masses. With the ample sample size afforded by our
multi-institutional RPN database, we performed a 1:4 matched
comparison between retroperitoneal and transperitoneal RPN,
focusing exclusively on the treatment of posterior tumors.
In our study, we confirm that the retroperitoneal and
transperitoneal RPN approaches achieve generally similar
surgical outcomes for posterior tumors. The main positive
finding was that retroperitoneal RPN affords approximately a
half-day shorter LOS, on average, compared with the trans-
peritoneal approach. While this difference was statistically
significant ( p = 0.01), the clinical and economic significance
of this difference remains to be seen. Due to the unblinded
retrospective nature of this study and the perceived benefit of
the retroperitoneal approach, surgeon bias may have influ-
enced discharge practice patterns in favor of patients treated
with retroperitoneal RPN. Aside from bias, multiple other
factors may have contributed to the shorter LOS seen with
retroperitoneal RPN. Faster gastrointestinal recovery, which
has been asserted as a potential advantage of the retroperi-
toneal approach, is one possible explanation for the shorter
LOS seen in this group; however, ileus rates were low (0.8%)
in our cohort and did not differ significantly between ap-
proaches. Decreased surgical morbidity and shorter operative
time, other potential benefits of the retroperitoneal approach,
also may have contributed to the shorter LOS. However,
neither complication rates nor operative times were found to
be significantly different between the retroperitoneal and
transperitoneal approaches in our analysis.
We also found a significant difference in WITs between
approaches, with the retroperitoneal approach associated
with two more minutes of warm ischemia than the transper-
itoneal approach. Nevertheless, since all surgeons were
highly experienced, WITs were short, primarily staying
within the 25-minute cutoff that is associated with an in-
creased risk of de novo stage IV chronic kidney disease.15,16
Furthermore, the difference in WIT between approaches did
not appear to be clinically significant in our study, causing no
difference in latest eGFR preservation. However, for novice
surgeons who may require longer WITs, this difference may
become clinically relevant. Other important surgical out-
comes, including intraoperative complications, major post-
operative complications, and positive surgical margin rates,
were roughly equivalent between approaches.
In the only other study to compare retroperitoneal (n = 116)
and transperitoneal (n= 97) RPN for posterior tumors, Kim
and colleagues showed that the transperitoneal approach was
associated with 7.4-fold higher odds of LOS greater than
1 day vs LOS equal to 1 day in logistic regression analysis.7
This effect was unusually high, 4.6-fold higher than the only
other significant predictor in their model—tumor size—and
confidence intervals were not supplied, raising concerns
about their statistical methodology. With only 76 events
(patients with LOS equal to 1 day) in the study and 12 pre-
dictor variables in their multivariable analysis, this model
may have been overfit, decreasing confidence in the reported
findings. Furthermore, the majority of retroperitoneal RPN
cases in their study were performed during the later years of
the study period, at a time of when early discharge care
pathways were being implemented nationally, yet they did
not account for treatment year in their multivariable model,
which may have further confounded their LOS results.17 By
comparison, in our study, we matched our groups for treat-
ment year to minimize potential bias associated with this
confounder.
Our study has limitations to acknowledge, including po-
tential bias related to the retrospective design, the inability to
Table 3. Secondary Outcomes by Approach
Outcomes Total TA RA p
Mean EBL –SD, mL 182– 215 190– 239 150 – 62 0.18
Mean WIT –SD,
minute
19– 8.3 19 – 8.5 21 – 6.9 0.01
Recurrence, n (%) 3 (0.8) 1 (0.3) 2 (2.7) 0.10
All-cause death, n (%) 2 (0.6) 2 (0.7) 0 1.00
Cancer-specific
death, n (%)
1 (0.4) 1 (0.5) 0 1.00
Bold type indicates statistical significance.
EBL = estimated blood loss; WIT =warm ischemia time.














































match 15% of retroperitoneal cases, and the inability to adjust
for unknown confounders. Furthermore, our findings may not
be generalizable to those of lower-volume hospitals or less
experienced surgeons. Last, while we did not find a difference
in disease recurrence or survival outcomes between ap-
proaches, longer follow-up is needed to confirm these findings.
Conclusions
In conclusion, for highly skilled robotic surgeons, retro-
peritoneal RPN is effective for the treatment of small (<4 cm)
renal masses. The retroperitoneal approach offers slightly
decreased LOS; however, the clinical and/or economic benefit,
if any, of this incremental improvement requires further study.
Ultimately, good results can be achieved with either approach;
therefore, surgeons should base the choice of surgical ap-
proach on their own clinical judgment and experience.
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ASA ¼ American Society of Anesthesiologists
physical status classification
BMI ¼ body mass index
eGFR ¼ estimated glomerular filtration rate
IQR ¼ interquartile range
LOS ¼ length of stay
R.E.N.A.L. ¼ radius, exophytic/endophytic properties,
nearness of tumor to the collecting
system or sinus, anterior/posterior,
location relative to polar lines
RPN ¼ robotic partial nephrectomy
WIT ¼ warm ischemia time
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